81![John C. Bell, PhD Senior Scientist, Cancer Therapeutics, Ottawa Hospital Research Institute Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology University of Ottawa Research Interests Oncolytic Viru John C. Bell, PhD Senior Scientist, Cancer Therapeutics, Ottawa Hospital Research Institute Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology University of Ottawa Research Interests Oncolytic Viru](https://www.pdfsearch.io/img/3718bfc009bf204cc14c0f91538499b6.jpg) | Add to Reading ListSource URL: www.montrealiums2014.orgLanguage: English - Date: 2014-05-26 14:19:19
|
---|
82![Acta Med. Okayama, 2011 Vol. 65, No. 3, pp. 151ン162 CopyrightⒸ 2011 by Okayama University Medical School. http://escholarship.lib.okayama-u.ac.jp/amo/ Acta Med. Okayama, 2011 Vol. 65, No. 3, pp. 151ン162 CopyrightⒸ 2011 by Okayama University Medical School. http://escholarship.lib.okayama-u.ac.jp/amo/](https://www.pdfsearch.io/img/2a7b7419b92e8eccb3d29b9daf15a4e7.jpg) | Add to Reading ListSource URL: www.lib.okayama-u.ac.jpLanguage: English - Date: 2011-06-27 22:01:26
|
---|
83![Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other](https://www.pdfsearch.io/img/2220768922a2633545ff763196ee9f1d.jpg) | Add to Reading ListSource URL: ohfoundation.caLanguage: English - Date: 2012-07-26 14:23:08
|
---|
84![PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation LONDON – 1 PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation LONDON – 1](https://www.pdfsearch.io/img/19df8e79110ddd23a87640b935e3a4a9.jpg) | Add to Reading ListSource URL: www.psioxus.comLanguage: English - Date: 2012-01-18 05:15:55
|
---|
85![Sarcopenia / Cachexia / Oncolytic virus / Medicine / Geriatrics / Rehabilitation medicine Sarcopenia / Cachexia / Oncolytic virus / Medicine / Geriatrics / Rehabilitation medicine](/pdf-icon.png) | Add to Reading ListSource URL: www.psioxus.comLanguage: English - Date: 2011-03-31 12:28:13
|
---|
86![PSIOXUS THERAPEUTICS RECEIVES £1.8 MILLION TRANSLATION AWARD FROM THE WELLCOME TRUST TO TAKE ONCOLYTIC VIRUS INTO CLINIC ColoAd1 will enter phase I/II development for metastatic colorectal cancer in 2012 LONDON –12 Se PSIOXUS THERAPEUTICS RECEIVES £1.8 MILLION TRANSLATION AWARD FROM THE WELLCOME TRUST TO TAKE ONCOLYTIC VIRUS INTO CLINIC ColoAd1 will enter phase I/II development for metastatic colorectal cancer in 2012 LONDON –12 Se](https://www.pdfsearch.io/img/18eb16d8f0035f75f1d99d28161604d4.jpg) | Add to Reading ListSource URL: www.psioxus.comLanguage: English - Date: 2011-12-20 03:27:39
|
---|
87![Early Success of Ark’s Manufacturing Partnership with PsiOxus Initiation of Toxicology Study for PsiOxus’s ColoAd1 Oncolytic Product London, UK - 4 January 2012, Ark Therapeutics Group plc (“Ark”) and PsiOxus The Early Success of Ark’s Manufacturing Partnership with PsiOxus Initiation of Toxicology Study for PsiOxus’s ColoAd1 Oncolytic Product London, UK - 4 January 2012, Ark Therapeutics Group plc (“Ark”) and PsiOxus The](https://www.pdfsearch.io/img/66146b1e962c89fe339f18d6315871c9.jpg) | Add to Reading ListSource URL: www.psioxus.comLanguage: English - Date: 2012-01-04 06:08:27
|
---|
88![FOR IMMEDIATE RELEASE PSIOXUS THERAPEUTICS SECURES £22 MILLION ($34 MILLION) IN SERIES B FINANCING TO DRIVE CLINICAL DEVELOPMENT FOR ONCOLYTIC VACCINE Investment to Advance ColoAd1 through Phase II Clinical Trial for FOR IMMEDIATE RELEASE PSIOXUS THERAPEUTICS SECURES £22 MILLION ($34 MILLION) IN SERIES B FINANCING TO DRIVE CLINICAL DEVELOPMENT FOR ONCOLYTIC VACCINE Investment to Advance ColoAd1 through Phase II Clinical Trial for](https://www.pdfsearch.io/img/6f9c3fcb4589e513776614fac821b30f.jpg) | Add to Reading ListSource URL: www.psioxus.comLanguage: English - Date: 2012-07-09 04:32:34
|
---|
89![INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 25 October 2006 ICH Considerations General Principles to Address the Risk of Inadvertent Germline Inte INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 25 October 2006 ICH Considerations General Principles to Address the Risk of Inadvertent Germline Inte](https://www.pdfsearch.io/img/60e97875525b791264f52e224bdfd8cd.jpg) | Add to Reading ListSource URL: www.ich.orgLanguage: English - Date: 2012-06-22 05:07:33
|
---|
90![INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009](https://www.pdfsearch.io/img/d0aa5b375212b084fcc2852cb4680517.jpg) | Add to Reading ListSource URL: www.ich.orgLanguage: English - Date: 2012-06-22 05:07:32
|
---|